|
The Faces of Cardiovascular Disease: Part 3
|
2
|
Resverlogix Corp.
|
Apr 02, 2019 02:37PM
|
|
The Faces of Cardiovascular Disease: Part 2
|
3
|
Resverlogix Corp.
|
Feb 26, 2019 07:46PM
|
|
The Faces of Cardiovascular Disease
|
3
|
Resverlogix Corp.
|
Jan 29, 2019 02:46PM
|
|
The Evolution of Apabetalone, Redux
|
10
|
Resverlogix Corp.
|
Apr 26, 2019 04:06PM
|
|
The countdown to 250
|
5
|
Resverlogix Corp.
|
Oct 10, 2018 12:35PM
|
|
The cardiac pre-print now published....in Cell!
|
17
|
Resverlogix Corp.
|
Mar 16, 2021 10:25AM
|
|
The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice
|
2
|
Resverlogix Corp.
|
Sep 29, 2017 12:14PM
|
|
The BET inhibitor mCRPC papers keep piling up
|
4
|
Zenith Epigenetics
|
Mar 21, 2018 11:33AM
|
|
The 3 inflection points: SSRA, Top-Line, Full Data
|
6
|
Resverlogix Corp.
|
Sep 09, 2018 06:40PM
|
|
Thanks in advance.....
|
1
|
Resverlogix Corp.
|
Dec 15, 2016 10:40AM
|
|
Thanks in advance....
|
1
|
Zenith Epigenetics
|
Dec 15, 2016 10:40AM
|
|
Technical Difficulties?
|
|
Resverlogix Corp.
|
Oct 10, 2017 04:55PM
|
|
Targeting Transcription Factors for Cancer Treatment
|
5
|
Zenith Epigenetics
|
Jun 22, 2018 10:59AM
|
|
Targeting Epigenetics as a New Therapy in Vascular Disease and Dementia
|
6
|
Resverlogix Corp.
|
Aug 29, 2019 06:30AM
|
|
Targeting bromodomain and extraterminal proteins in breast cancer
|
3
|
Zenith Epigenetics
|
Nov 27, 2017 12:41PM
|
|
Target modulation
|
8
|
Zenith Epigenetics
|
Dec 20, 2016 12:44PM
|
|
Tailwinds Research Group "biOasis Breaking Out of Downtrend?"
|
1
|
BIOASIS TECHNOLOGIES INC
|
Sep 18, 2017 10:43AM
|
|
Tailwinds Research biOasis video
|
1
|
BIOASIS TECHNOLOGIES INC
|
Nov 18, 2016 10:47AM
|
|
Sure would be nice to get an update on the MTfp-TZM program
|
2
|
BIOASIS TECHNOLOGIES INC
|
Feb 11, 2016 11:02PM
|
|
Summary of Proposed BETonMACE2 design and timelines
|
15
|
Resverlogix Corp.
|
Feb 05, 2021 07:43AM
|
